This metabolite incorporates a PDE selectivity profile similar to sildenafil and an in vitro potency for PDE5 approximately 50% from the father or mother drug. Plasma concentrations of the metabolite are about 40% of All those observed for sildenafil, so which the metabolite accounts for approximately 20% of sildenafil's pharmacologic outcomes.Use